[Bairen Medical: The innovative product valved patch for complex congenital heart disease was approved for registration] On September 23, Bairen Medical (688198.SH) announced that the company’s independently developed innovative product valved patch for complex congenital heart disease was approved for registration by the State Food and Drug Administration. This product is suitable for surgical implantation in children under 2 years old with complex congenital heart disease, and can be used for patients with pulmonary artery stenosis or atresia, tetralogy of Fallot, and other patients who need to reconstruct the right ventricular outflow tract. The product is divided into two models: single-valve type and double-valve type, which can widen the right ventricular outflow tract and effectively prevent reflux and protect right heart function. The actual sales of this product after its launch is affected by marketing promotion and other factors, and the impact on future revenue cannot yet be predicted.